Pro 2013-021 (Jianfeng Group Corporate Bond Listing Announcement)-5
Release time:
2020-08-05
Section VII Description of Bond Follow-up Rating Arrangement
According to the relevant regulations of the regulatory authorities and the relevant requirements of United Rating on follow-up rating, United Rating will conduct a regular follow-up rating on this bond within months after the annual report of the issuer is announced during the effective duration of this bond, and during the term of this bond, no regular tracking rating will be carried out according to the relevant circumstances.
Issuers should provide relevant financial reports and other relevant information as required by the Joint Rating Tracking Rating Information List. The issuer shall promptly notify the joint rating and provide relevant information in the event of major changes or major events that may have a significant impact on the credit rating.
Joint rating will pay close attention to the operation and management status and relevant information of the issuer. If major changes are found in the relevant elements of the issuer or this bond, or the existence or occurrence of major events that may have a greater impact on the credit rating, Joint rating will implement the relevant situation and assess its impact on the credit rating in a timely manner, to confirm or adjust the credit rating of the bonds.
If the issuer is unable to provide the relevant information and circumstances required for the above-mentioned tracking rating in a timely manner, Joint Rating will analyze and adjust the credit rating according to the relevant circumstances, and if necessary, the credit rating may be released temporarily until the issuer provides the relevant information.
tracking rating results will be published on the joint credit rating website ( www.lianheccreditrating.com.cn ), Shanghai Stock Exchange website (www.sse.com.cn ) and Juchao Information Network (www.cninfo.com.cn ) and submitted to issuers, regulatory authorities, trading institutions, etc.
Section VIII Bond Guarantee Basic Information
This corporate bond is guaranteed by Tasly Group with full unconditional and irrevocable joint and several liability guarantee.
Basic Information of 1. Guarantor
Overview of (I) Guarantor
Company Name: |
Tianjin Tianshili Group Co., Ltd. |
Company Domicile: |
Tianjin Beichen Science and Technology Park |
Legal Representative: |
Yan Xijun |
Registered Capital: |
23,784.38 million Yuan |
Paid-in Capital: |
23,784.38 .13 million Yuan |
Date of Establishment: |
2000 # December August 30 |
Business Scope: |
Foreign Investment and Holding; Planting of natural plant drugs and related processing and separation; organize subordinate enterprises to carry out product production, scientific research, sales, import and export business; wholesale and retail of all kinds of goods and materials; technology development, consultation, service, transfer of biotechnology (excluding drug production and sales) and products; lease of self-owned equipment and houses; all kinds of economic information consultation; export business of technology developed and scientific research products produced by the enterprise; import of technology, raw and auxiliary materials, mechanical equipment, instruments and spare parts required by the enterprise for scientific research and production; The enterprise's feed processing and "three to one supplement" business; Mining development and operation; Production of raw materials (fexofenadine hydrochloride, right zopiclone); Internet information services (information services other than news, publishing, education, medical devices and electronic announcements, business coverage: tianjin) |
(II) Guarantor's Main Financial Data and Indicators for the Last Two Years
According to Tianshili Group 2012 Year and 2011 Year Consolidated Financial Statements, the main financial indicators (consolidated caliber) are as follows (among them, 2012 financial statements were audited by Tianjian Certified Public Accountants (Special General Partnership) and issued an unqualified audit report of Tianjian Audit [2013]1490 . 2011 financial statements were audited by Tianjian Certified Public Accountants (Special General Partnership), and issued an unqualified audit report of Tianjian Audit [2012]1259 ):
Project |
2012 June 31 |
2011 # June |
# Total 205 Assets (RMB 10,000) |
1,086,359.73 |
1,041,815.88 |
# Total 222 Liabilities (RMB 10,000) |
635,002.04 |
634,383.72 |
Total Owner's Equity (RMB 10,000) |
451,357.69 |
407,432.16 |
belongs to the owner's equity of the parent company (RMB 10,000) |
192,319.11 |
169,366.60 |
Asset-liability Ratio () |
58.45 |
60.89 ################### | 288
1.36 |
Quick Ratio (Times) |
1.10 |
1.15 |
Project |
2012 | Year
2011 Year |
996,963.81 |
|
927,977.29 |
Total Profit (RMB 10,000) |
95,489.91 |
86,209.96 |
Net Profit (RMB 10,000) |
74,862.82 |
66,824.87 |
Net Profit Attributed to Owners of Parent Company |
36,309.41 |
24,656.81 |
Return on Net Assets ( |
) |
17.01 |
The calculation method of the above financial indicators is as follows: |
asset-liability ratio = total liabilities | /
current ratio =
current assets/ current liabilities
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31